PROCEPT Biorobotics Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by PROCEPT Biorobotics Corporation on March 5, 2026. The filing reports corporate governance changes effective immediately as of the report date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and does not contain financial statements or performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Appointment: Mr. Daniel Puckett was appointed as a new Class III director and as a member of the Audit Committee.
- Term Details: Mr. Puckett's initial term expires at the 2027 annual meeting of stockholders.
Management Commentary and Risks
The Board determined that Mr. Puckett qualifies as an "independent director" under SEC and Nasdaq rules. His compensation will align with the Company's standard Non-Employee Director Compensation Program. The filing confirms no undisclosed arrangements or transactions involving Mr. Puckett requiring reporting under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify Mr. Puckett's specific compensation package details in the definitive proxy statement filed on April 25, 2025.
- Confirm the impact of the new Audit Committee member on upcoming financial oversight and audit processes.
- Review Mr. Puckett's prior experience as CFO of Shockwave Medical, Counsyl, and Ariosa Diagnostics for strategic alignment.